Angiogenesis biomarkers, particularly sFlt-1 and PlGF, represent valuable tools for predicting, diagnosing, and monitoring FGR. Their integration into clinical practice could optimize risk stratification and management, ultimately reducing adverse perinatal outcomes.
No takes yet. Share an insight, caveat, or question.
Villalaín et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: